Beijing Guangwei Pharmaceutical Technology

Beijing Guangwei Pharmaceutical Technology is a clinical-stage biotechnology company specializing in the development of Live Biotherapeutic Products (LBPs). The company utilizes a proprietary platform for the isolation, characterization, and anaerobic cultivation of gut-derived microorganisms to address immune-mediated and metabolic diseases. Its lead program, GW-001, is currently in clinical trials for the treatment of Graft-versus-Host Disease (GvHD) in patients undergoing stem cell transplantation. Guangwei Pharmaceutical is also advancing a pipeline of microbial candidates for inflammatory bowel disease and oncology. Headquartered in Beijing, the firm is supported by leading venture capital investors and maintains state-of-the-art GMP manufacturing capabilities for microbial drugs.